Company Market News

Centessa Pharmaceuticals plc (NASDAQ: CNTA)
8:00 PM UTC, 06/20/25
Last: $12.43 Change: -0.25 %Change: -1.97% Volume: 1,612,616
Centessa Gets US FDA's Clearance to Start Phase 1 Trial of ORX142 for Neurological, Neurodegenerative Disorders

Back

Last updated: 06/16/2025 10:32:59 AM

10:32 AM EDT, 06/16/2025 (MT Newswires) -- Centessa Pharmaceuticals (CNTA) said Monday it has received clearance for its investigational new drug application from the US Food and Drug Administration to start a phase 1 clinical trial of ORX142 in healthy participants.

The company said it is developing ORX142 to treat select neurological and neurodegenerative disorders.

Centessa said it will evaluate the safety, tolerability, and pharmacokinetics of single-ascending doses and multiple-ascending doses of ORX142 in the participants, adding that it intends to start the first-in-human phase 1 clinical trial this year.

Shares of the company were down 1.5% in recent Monday trading.

Price: 12.20, Change: -0.18, Percent Change: -1.46

http://www.mtnewswires.com
Copyright © 2025 MT Newswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.




Quotes displayed with 15 minutes delay. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement. News provided by MT Newswires, a Division of MidnightTrader, Inc. Events Data provided by Wall Street Horizon. ©2020 Wall Street Horizon, Inc.